Jacob Appelbaum

Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

E. Estey, J. Abkowitz, M. Othus, 2022, Cancers.

Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms

E. Estey, M. Sorror, M. Othus, 2022, Leukemia.

A Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

E. Estey, J. Abkowitz, M. Othus, 2021, Blood.

SARS-CoV-2 spike-dependent platelet activation in COVID-19 vaccine-induced thrombocytopenia

J. Kelton, James W. Smith, D. Arnold, 2021, Blood Advances.

Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agents

E. Estey, M. Othus, R. Walter, 2023, Leukemia & lymphoma.

Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms

E. Estey, M. Othus, R. Walter, 2023, Leukemia.

Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML

E. Estey, J. Abkowitz, M. Othus, 2023, Blood Advances.